Drug Pricing in Trump 2.0: Where are We and What’s Ahead?

Over the past year, the Trump Administration has built on Biden-era efforts to lower drug prices while also advancing several new initiatives. Ongoing Medicare drug price negotiations, “most-favored-nation” proposals, direct-to-consumer deals with pharmaceutical companies, and questions about the impact of tariffs on drug costs have kept prescription drug pricing in the spotlight. This panel will bring together experts to explore the evidence for whether these initiatives are likely to deliver meaningful relief for consumers and to discuss what to expect from drug pricing policy under the current administration.

Supported by the Charles C. Leighton, MD Memorial Fund.

Speakers

Avik Roy

Co-Founder and Chairman, Foundation for Research on Equal Opportunity

Rachel Sachs, JD, MPH

Professor, Law, Washington University School of Law

Marta Wosinska, PhD

Senior Fellow, Economic Studies, Center on Health Policy, Brookings Institute

Rachel M. Werner, MD, PhD (moderator)

Executive Director, Penn LDI; Robert D. Eilers Memorial – William Maul Measey Professor in Health Care Management and Economics, Wharton School; Professor, Medicine, Perelman School of Medicine